Pneuma Respiratory, Inc., a Boone, North Carolina-based developer of a breath-activated digital inhaler (BDI), received a $10m equity investment.
Haisco Pharmaceutical Group Co, Ltd, a China-based company focused on the research and development and marketing of therapeutic drugs, made the investment.
As part of an overall agreement, Haisco is to receive rights to distribute Pneuma Respiratory’s pharmaceutical products in China and will be responsible for funding China regulatory filings.
Launched in 2015 by Eric Hunter, CEO, Pneuma Respiratory is a pharmaceutical company that has developed the PNEUMAHALER™ Breath Actuated Digital Inhaler (BDI) to solve the problems of existing metered dose, dry- powder, and soft-mist inhalers to improve the efficacy of currently available airway medications.
PNEUMAHALER BDI is a pulmonary inhaler that merges advanced droplet ejector technology with digitally controlled breath-actuation, and package it in a lightweight, pocket-sized device.
The inhaled delivery system has integrated Bluetooth technology to provide feedback on drug delivery to patients, family members and health care providers.